You have read all your free articles, to continue reading subscribe to read the rest of this content.
The first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating Nektar’s CD122-preferential IL-2 pathway agonist with Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). “We’re pleAlready a subscriber Login You have read all your…
Hansa Medical and Axis-Shield report most promising results from pivotal clinical trial with HBP-analysis. The clinical study was carried out at Emergency Departments both in Sweden and the US through 2011-2013. Results show that HBP-analysis predicts patients with forthcoming severe inflammatoryAlready a subscriber Login You have read all your free…
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer (NSCLC) patients harboring Already a subscriber Login You have…
Nordic Nanovector announces that the first clinical site in the United States (in Long Beach, CA) for the pivotal PARADIGME trial has been initiated to enable enrolment of patients. PARADIGME is a global randomised Phase 2b clinical trial comparing two Betalutin (177Lu-satetraxetan-lilotomab) dosAlready a subscriber Login You have read all…
